Liraglutide (Victoza) vs Semaglutide (Ozempic)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

Liraglutide (Victoza)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT00318461 · Phase 3 · completed

This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.

Next expected readout: June 2027 · NCT03883412 (registry estimate)

Reported efficacy

Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00318461

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)

Result source: NCT03819153

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLiraglutide (Victoza)Semaglutide (Ozempic)
HbA1c, change-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
Body weight, change (kg)-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
HbA1c below 7%63.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484
Fasting plasma glucose, change-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
3-point MACE (% with event)13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT011790486.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153

HbA1c, change

Liraglutide (Victoza)
-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422
Semaglutide (Ozempic)
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450

Body weight, change (kg)

Liraglutide (Victoza)
-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
Semaglutide (Ozempic)
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352

HbA1c below 7%

Liraglutide (Victoza)
63.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
Semaglutide (Ozempic)
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484

Fasting plasma glucose, change

Liraglutide (Victoza)
-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
Semaglutide (Ozempic)
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984

3-point MACE (% with event)

Liraglutide (Victoza)
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048
Semaglutide (Ozempic)
6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
23 other shared endpoints and safety

Coverage. Liraglutide (Victoza): 27 of 27 rows · Semaglutide (Ozempic): 27 of 27 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Victoza)
Rows use multiple source trials
Semaglutide (Ozempic)
Rows use multiple source trials
BMI
absolute change · kg
-1.3 vs -1.2 Oral Antidiabetic Drug kg @ 104wk1.8 mga,b,c,d
NCT02730377 · Phase 4 · registry result, not featured evidence
-5.3 vs -1.6 placebo kg @ 72wk7.2 mga,b,c,d
NCT05649137 · Phase 3 · registry result, not featured evidence
DBP
absolute change · mmHg
-0.72 vs -1.12 placebo mmHg @ 26wkb,c,e
NCT02964247 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.8 placebo mmHg @ 104wkb,c,e
NCT03819153 · Phase 3
1 other source trial
-1.9 vs -1.4 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=200) @ 32wkf,g,c,h
NCT02298192 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.01% (n=189) @ 32wk
NCT02298192 · Phase 3 · registry result, not featured evidence
-1.23% (n=91) @ 52wkg,c,h
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-0.86% (n=335) @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
HbA1c Decrease 1 0
responder rate · % of participants
52.31% (n=195) vs 16.84% (n=95) placebo @ 26wkg,c,i
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
76.5% (n=293) vs 48.6% (n=313) Canagliflozin @ 52wkg,c,i
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain
responder rate · % of participants
47.69% (n=195) vs 19.15% (n=94) placebo @ 26wkg,c,i
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
69.6% (n=293) vs 45% (n=313) Canagliflozin @ 52wkg,c,i
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain
event count · % of participants
13.7% (n=270) vs 8.3% (n=265) Insulin Degludec @ 52wk*f,j,g,c
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 37 Participants as posted
show 1 more dose
52% (n=271) vs 8.3% (n=265) Insulin Degludec @ 52wk*
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 141 Participants as posted
48.5% (n=410) vs 37.3% (n=426) Standard of Care @ 52wk*j,g,c
Yes
NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 199 Participants as posted
HbA1c Less Than 7%
event count · % of participants
48.2% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mgj,g,c
Yes
NCT01541215 · Phase 3 · converted to % from 27 Participants as posted
2 other source trials
89.1% (n=275) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 245 Participants as posted
76.2% (n=273) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 208 Participants as posted
56.7% (n=430) vs 48.9% (n=462) Standard of Care @ 52wk*j,g,c
Yes
NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 244 Participants as posted
HbA1c Less Than 7%
event count · % of participants
No placebo or comparator arm
89.5% (n=200) @ 32wk*f,j,g,c,k
NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 179 participants as posted
show 1 more dose
89.9% (n=189) @ 32wk*
NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 170 participants as posted
56.5% (n=92) @ 24wk*j,g,c,k
Yes
NCT05533632 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted
HbA1c Less Than or Equal to 6.5
event count · % of participants
44.6% (n=56) vs 25% (n=52) placebo @ 52wk*1.8 mgl,m,c,n
Yes
NCT01541215 · Phase 3 · converted to % from 25 Participants as posted
72.6% (n=288) vs 16% (n=94) placebo @ 72wk*7.2 mgl,m,c,n
NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 209 Participants as posted
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
61.7% (n=162) vs 26.3% (n=175) Sitagliptin @ 26wkl,a,g,c,i
NCT02008682 · Phase 4 · registry result, not featured evidence
1 other source trial
34.36% (n=195) vs 9.47% (n=95) placebo @ 26wk
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
62.1% (n=293) vs 26.8% (n=313) Canagliflozin @ 52wkl,a,g,c,i
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HbA1c Reduction 1% and Weight Loss 3%
responder rate · % of participants
29.74% (n=195) vs 7.45% (n=94) placebo @ 26wkg,c,i
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
57.3% (n=293) vs 34.8% (n=313) Canagliflozin @ 52wkg,c,i
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HDL Cholesterol
ratio to baseline · ratio
1.01 vs 1.02 Insulin Degludec ratio @ 26wkf,b,c,i
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
1.03 vs 1.02 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
1.04 vs 0.99 placebo ratio @ 52wkb,c,i
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
1 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
1.04 vs 1.08 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
Hypoglycemia Episodes Level 2 or 3
event count · count
38 vs 36 Insulin Degludec count @ 26wkb,c,o
NCT03175120 · Phase 3 · registry result, not featured evidence
22 vs 46 Insuline Glargine U100 (Titrated) count @ 40wkb,c,o
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
2 other source trials
3 vs 3 Dulaglutide count0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
7 vs 3 Dulaglutide count1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
LDL Cholesterol
ratio to baseline · ratio
0.92 vs 1.01 Insulin Degludec ratio @ 26wkf,b,c,i
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.96 vs 1.01 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.99 vs 1.03 placebo ratio @ 52wkb,c,i
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
1 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
0.96 vs 1.05 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
PPG Excursion
absolute change · mmol/L
-0.747 vs -0.397 placebo mmol/L @ 52wk1.8 mgg,c
NCT01541215 · Phase 3
2 other source trials
-0.74 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.01 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.9 Insulin Aspart mmol/L @ 52wkg,c
NCT03689374 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-1.95 vs -3.35 placebo mmHg @ 26wkb,c,e
NCT02964247 · Phase 3 · registry result, not featured evidence
-3.9 vs -1.4 placebo mmHg @ 104wkb,c,e
NCT03819153 · Phase 3
1 other source trial
-3 vs -2.8 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
SMBG 7-point
absolute change · mmol/L
-2.309 vs -0.748 placebo mmol/L @ 52wk1.8 mgg,c
NCT01541215 · Phase 3
-2.1 vs -2.1 Insulin Aspart mmol/L @ 52wkg,c
NCT03689374 · Phase 3 · registry result, not featured evidence
1 other source trial
-2.8 vs -1.9 Canagliflozin mmol/L @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
Total Cholesterol
ratio to baseline · ratio
0.94 vs 0.99 Insulin Degludec ratio @ 26wkf,b,c,i
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.97 vs 0.99 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.96 vs 1 placebo ratio @ 52wkb,c,i
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
1 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
0.96 vs 1.03 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
Triglyceride
ratio to baseline · ratio
0.88 vs 0.82 Insulin Degludec ratio @ 26wkf,b,c,i
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.9 vs 0.82 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.8 vs 0.95 placebo ratio @ 52wkb,c,i
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
0.9 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
0.86 vs 0.92 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
VLDL Cholesterol
ratio to baseline · ratio
0.9 vs 0.84 Insulin Degludec ratio @ 26wkf,p,g,q
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.92 vs 0.84 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.95 vs 0.86 placebo ratio @ 34wk21.6 mgf,p,g,q
NCT05144984 · Phase 2 · registry result, not featured evidence
show 4 more doses
0.72 vs 0.86 placebo ratio @ 34wk2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
0.75 vs 0.86 placebo ratio @ 34wk2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
0.78 vs 0.86 placebo ratio @ 34wk2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
0.76 vs 0.86 placebo ratio @ 34wk2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Waist Circumference Change
absolute change · cm
2.5 vs 3.4 Insulin Degludec cm @ 52wkf,g,c
NCT02607306 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.1 vs 3.4 Insulin Degludec cm @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-3.3 vs 2.1 Insulin Aspart cm @ 52wkg,c
NCT03689374 · Phase 3 · registry result, not featured evidence
1 other source trial
-4.2 vs -3 Canagliflozin cm @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
Weight
percent change · % of baseline
-7.2% (n=35) vs -3.1% (n=37) placebo @ 84wkj,g,c,r
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
-4.47% (n=389) vs -2.68% (n=386) Standard of Care @ 104wkj,g,c,r
NCT03596450 · Phase 4 · registry result, not featured evidence
Weight Loss 3%
responder rate · % of participants
46.43% (n=196) vs 41.24% (n=97) placebo @ 26wkg,c,i
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
68.8% (n=298) vs 64.9% (n=313) Canagliflozin @ 52wkg,c,i
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
21.1%1.8 mg dailys
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
18.3%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
3%
NCT01179048 · Phase 3
15.2%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
41.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
55.2%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
6.3%
NCT02765399 · Phase 4 · registry result, not featured evidence
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
8.6%
NCT01505673 · Phase 4 · registry result, not featured evidence
7.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
14.7%
NCT02008682 · Phase 4 · registry result, not featured evidence
15.1%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
16.1%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
55.1%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
1.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
3.7%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
1.3%1.0 mgt
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
1.7%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.4%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
7.8%0.5 mg weekly
NCT02054897 · Phase 3
5.1%1.0 mg weekly
NCT01930188 · Phase 3 · combination
5.4%0.5 mg weekly
NCT01930188 · Phase 3 · combination
5.3%1.0 mg/week
NCT02128932 · Phase 3
7.5%0.5 mg/week
NCT02128932 · Phase 3
3.8%2.0 mg weekly
NCT03989232 · Phase 3
2.1%1.0 mg weekly
NCT03989232 · Phase 3
3.8%1.0 mg weekly
NCT02305381 · Phase 3
3.8%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
10.6%
NCT05533632 · Phase 4 · registry result, not featured evidence
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
28.1%
NCT03596450 · Phase 4 · registry result, not featured evidence
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
1.7%Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
3.9%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
18.3%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
7.6%
NCT04560998 · Phase 3 · registry result, not featured evidence
1.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
9.7%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
8.7%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.9%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
2.6%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
7.3%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
4.1%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.5%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.9%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
8.2%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
11.3%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
12.9%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
3.9%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.7%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
12%1.8 mg dailys
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
9.5%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT01179048 · Phase 3
0%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—
NCT03260881 · Phase 4 · registry result, not featured evidence
7.4%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
7.9%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
—
NCT02765399 · Phase 4 · registry result, not featured evidence
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
—
NCT02014740 · Phase 4 · registry result, not featured evidence
—
NCT02299388 · Phase 4 · registry result, not featured evidence
—
NCT01505673 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01973231 · Phase 4 · registry result, not featured evidence
—
NCT02008682 · Phase 4 · registry result, not featured evidence
6.4%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
8.3%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
—
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
—
NCT02964247 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.2%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
—1.0 mgt
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
—0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT03819153 · Phase 3
—1.0 mg weekly
NCT02054897 · Phase 3
—0.5 mg weekly
NCT02054897 · Phase 3
—1.0 mg weekly
NCT01930188 · Phase 3 · combination
—0.5 mg weekly
NCT01930188 · Phase 3 · combination
—1.0 mg/week
NCT02128932 · Phase 3
—0.5 mg/week
NCT02128932 · Phase 3
—2.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT02305381 · Phase 3
—0.5 mg weekly
NCT02305381 · Phase 3
—
NCT04126603 · Phase 4 · registry result, not featured evidence
—
NCT05786521 · Phase 4 · registry result, not featured evidence
3.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
2.2%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
—
NCT04560998 · Phase 3 · registry result, not featured evidence
—
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
—1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
0%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
—2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
6.6%1.8 mg dailys
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
10.4%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
49.7%
NCT01179048 · Phase 3
13.6%1.8 mg
NCT01541215 · Phase 3
13.5%1.8 mg
NCT01541215 · Phase 3
4.2%1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
38.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
9.4%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
0%
NCT02765399 · Phase 4 · registry result, not featured evidence
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
2.9%
NCT01505673 · Phase 4 · registry result, not featured evidence
3%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.9%
NCT01973231 · Phase 4 · registry result, not featured evidence
1.6%
NCT02008682 · Phase 4 · registry result, not featured evidence
1.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02889510 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
7.8%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
5.1%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
0%
NCT01937598 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
33.6%1.0 mgt
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
35%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
9.4%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
49.6%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
5.5%0.5 mg weekly
NCT02054897 · Phase 3
7.3%1.0 mg weekly
NCT01930188 · Phase 3 · combination
7.3%0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.7%1.0 mg/week
NCT02128932 · Phase 3
6.1%0.5 mg/week
NCT02128932 · Phase 3
4.4%2.0 mg weekly
NCT03989232 · Phase 3
5.2%1.0 mg weekly
NCT03989232 · Phase 3
9.2%1.0 mg weekly
NCT02305381 · Phase 3
6.1%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
1%
NCT05533632 · Phase 4 · registry result, not featured evidence
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
6%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
5.9%INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
9.8%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
19.7%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
18.7%
NCT04560998 · Phase 3 · registry result, not featured evidence
6.2%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
7.4%
NCT03689374 · Phase 3 · registry result, not featured evidence
6.6%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.3%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
4.6%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
5.9%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
4.7%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7.7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5.6%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
7.9%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
5.8%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
6.7%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
1.6%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.3%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
2.6%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
7.8%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
6.5%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
4.1%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
1.8 mg dailys
nausea 21.5%
diarrhoea 16.5%
nasopharyngitis 14.9%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 32 more results
1.2 mg daily
nausea 17.5%
nasopharyngitis 15%
headache 14.2%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6 mg daily
nasopharyngitis 17.8%
diarrhoea 12.8%
nausea 12.4%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
nausea 11.1% (placebo 2.8%)
diarrhoea 5.7% (placebo 2.2%)
NCT01179048 · Phase 3
1.8 mg
nausea 28.8% (placebo 13.2%)
vomiting 25.8% (placebo 8.8%)
diarrhoea 22.7% (placebo 16.2%)
NCT01541215 · Phase 3
1.8 mg
nasopharyngitis 3.8% (placebo 27.9%)
vomiting 3.8% (placebo 8.8%)
abdominal pain 1.9% (placebo 7.4%)
NCT01541215 · Phase 3
1.8 mg
hyperglycaemia 2.1% (placebo 5.9%)
pharyngitis 2.1% (placebo 5.9%)
abdominal pain 0% (placebo 7.4%)
NCT01541215 · Phase 3
abdominal distention 31.6%
nausea 31.6%
NCT03260881 · Phase 4 · registry result, not featured evidence
1.8 mg
nausea 6.6%
NCT02730377 · Phase 4 · registry result, not featured evidence
nausea 25% (placebo 14.3%)
NCT02765399 · Phase 4 · registry result, not featured evidence
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
nausea 29.1%
NCT02014740 · Phase 4 · registry result, not featured evidence
nausea 31.4% (placebo 19.4%)
decreased in apetite 17.1% (placebo 11.1%)
diarrhea 11.4% (placebo 8.3%)
NCT01505673 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 16.3%
decreased appetite 8.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 12.4%
lipase increased 8.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
nausea 14.8%
decreased appetite 10.9%
diarrhoea 8.2%
NCT02008682 · Phase 4 · registry result, not featured evidence
vomiting 5.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal disorders 27.1% (placebo 5.7%)
general disorders and administration site conditions 2.9% (placebo 0%)
nervous system disorders 2.9% (placebo 2.9%)
NCT02889510 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
decreased appetite 14.4%
diarrhoea 14.4%
lipase increased 12.2%
NCT03172494 · Phase 3 · registry result, not featured evidence
nausea 37.2% (placebo 2.7%)
diarrhea 17.9% (placebo 17.3%)
allergic reaction to liraglutide 1.3% (placebo 0%)
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nausea 26.2% (placebo 6%)
decreased appetite 9.4% (placebo 0%)
diarrhoea 9.4% (placebo 3%)
NCT02964247 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 34.4%
constipation 13.9%
diarrhoea 8.8%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
headache 12.5% (placebo 12.5%)
asympomatic hyppglycaemia 6.3% (placebo 0%)
nausea 6.3% (placebo 0%)
NCT01937598 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
1.0 mgt
nausea 21.8% (placebo 7.5%)
diarrhoea 18% (placebo 11.8%)
vomiting 14.8% (placebo 5.1%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 42 more results
0.5 mg
diarrhoea 17.9% (placebo 11.8%)
nausea 17.3% (placebo 7.5%)
lipase increased 11.4% (placebo 8%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
1.0 mg
nausea 22.3%
diarrhoea 11.4%
lipase increased 10.1%
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
diabetic retinopathy 19.2% (placebo 18.4%)
covid-19 12.5% (placebo 13.9%)
NCT03819153 · Phase 3
1.0 mg weekly
nausea 23.8% (placebo 7.8%)
diarrhoea 10.8% (placebo 2.3%)
headache 6.9% (placebo 6.2%)
NCT02054897 · Phase 3
0.5 mg weekly
nausea 20.3% (placebo 7.8%)
diarrhoea 12.5% (placebo 2.3%)
headache 11.7% (placebo 6.2%)
NCT02054897 · Phase 3
1.0 mg weekly
nausea 17.6%
diarrhoea 13%
vomiting 10%
NCT01930188 · Phase 3 · combination
0.5 mg weekly
nausea 17.8%
diarrhoea 13%
nasopharyngitis 12.2%
NCT01930188 · Phase 3 · combination
1.0 mg/week
nausea 22.2%
diarrhoea 19.2%
vomiting 10.3%
NCT02128932 · Phase 3
0.5 mg/week
nausea 21.3%
diarrhoea 16.3%
nasopharyngitis 12.4%
NCT02128932 · Phase 3
2.0 mg weekly
nausea 14.4%
diarrhoea 9.4%
vomiting 7.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 14.6%
diarrhoea 8.8%
vomiting 6.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 16.8% (placebo 4.5%)
vomiting 11.5% (placebo 3%)
diarrhoea 6.9% (placebo 1.5%)
NCT02305381 · Phase 3
0.5 mg weekly
nausea 11.4% (placebo 4.5%)
lipase increased 9.1% (placebo 3%)
nasopharyngitis 8.3% (placebo 10.5%)
NCT02305381 · Phase 3
abdominal pain 60%
NCT05786521 · Phase 4 · registry result, not featured evidence
nausea 11.5%
diarrhea 5.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nausea 18.4%
diarrhoea 13.5%
vomiting 9.7%
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
7.2 mg
nausea 29% (placebo 11.8%)
diarrhoea 18.2% (placebo 8.8%)
vomiting 16.6% (placebo 2.9%)
NCT05649137 · Phase 3 · registry result, not featured evidence
1.0 mg
covid-19 5.6% (placebo 0%)
decreased appetite 5.6% (placebo 0%)
diabetic retinopathy 5.6% (placebo 5.7%)
NCT04865770 · Phase 3 · registry result, not featured evidence
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3 · registry result, not featured evidence
covid-19 14.4%
diarrhoea 12.1%
nausea 11.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 14.8%
diarrhoea 7.4%
nasopharyngitis 6.5%
NCT03689374 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
diarrhoea 16.9%
nausea 13.4%
upper respiratory tract infection 13.1%
NCT03061214 · Phase 3 · registry result, not featured evidence
0.5 mg weekly
diarrhoea 20.2%
upper respiratory tract infection 9.8%
lipase increased 7.7%
NCT03061214 · Phase 3 · registry result, not featured evidence
nausea 22.7%
diarrhoea 15.1%
vomiting 12.8%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1.0 mg
nausea 21.5%
diarrhoea 15.6%
decreased appetite 10.4%
NCT03191396 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
nausea 19.3% (placebo 3.3%)
diarrhoea 11.3% (placebo 6%)
vomiting 9.3% (placebo 2%)
NCT03086330 · Phase 3 · registry result, not featured evidence
1.0 mg
nausea 21%
diarrhoea 13.7%
vomiting 10.3%
NCT02648204 · Phase 3 · registry result, not featured evidence
0.5 mg
nausea 22.3%
diarrhoea 14.3%
vomiting 10%
NCT02648204 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 31.1%
nausea 19.1%
diarrhoea 15.8%
NCT02207374 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 33.9%
constipation 18.4%
nausea 12.1%
NCT02207374 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 17.6%
nausea 12.7%
constipation 11.8%
NCT02254291 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16.5%
constipation 14.6%
nausea 10.7%
NCT02254291 · Phase 3 · registry result, not featured evidence
2.0 mg
nausea 21.7% (placebo 15.3%)
vomiting 18.3% (placebo 6.8%)
diarrhoea 15% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
16.0 mg
nausea 37.1% (placebo 15.3%)
vomiting 25.8% (placebo 6.8%)
diarrhoea 21% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
8.0 mg
nausea 41.7% (placebo 15.3%)
diarrhoea 33.3% (placebo 11.9%)
vomiting 23.3% (placebo 6.8%)
NCT05486065 · Phase 2 · registry result, not featured evidence
21.6 mg
injection site erythema 10.2% (placebo 0%)
injection site reaction 10.2% (placebo 0%)
diarrhoea 8.5% (placebo 11.5%)
NCT05144984 · Phase 2 · registry result, not featured evidence
2.4 mg + 12.0 mg
diarrhoea 14.3% (placebo 11.5%)
constipation 9.1% (placebo 1.6%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 2.4 mg
nausea 19.5% (placebo 1.6%)
diarrhoea 14.3% (placebo 11.5%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 21.6 mg
diarrhoea 13% (placebo 11.5%)
nausea 13% (placebo 1.6%)
covid-19 11.7% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 7.2 mg
diarrhoea 21.6% (placebo 11.5%)
lipase increased 12.2% (placebo 3.3%)
nausea 12.2% (placebo 1.6%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 72 weeks versus 104 weeks.
  5. eAssessment timepoints differ: 104 weeks versus 26 weeks.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gPopulation comparability has not been reviewed for both studies.
  8. hAssessment timepoints differ: 52 weeks versus 32 weeks.
  9. iAssessment timepoints differ: 52 weeks versus 26 weeks.
  10. jTrial phases differ: Phase 4 versus Phase 3.
  11. kAssessment timepoints differ: 24 weeks versus 32 weeks.
  12. lThe reported result categories differ.
  13. mPopulation context differs: registered conditions differ; age eligibility differs (adolescents and adults versus includes children).
  14. nAssessment timepoints differ: 72 weeks versus 52 weeks.
  15. oAssessment timepoints differ: 40 weeks versus 26 weeks.
  16. pTrial phases differ: Phase 2 versus Phase 3.
  17. qAssessment timepoints differ: 34 weeks versus 26 weeks.
  18. rAssessment timepoints differ: 104 weeks versus 84 weeks.
  19. sPopulation comparability has not been reviewed for 32 of these studies.
  20. tPopulation comparability has not been reviewed for 43 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Victoza)

MACE Broad 20.3% (n=4668) vs 22.7% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
All-cause Mortality 8.2% (n=4668) vs 9.6% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Microvascular Composite 7.6% (n=4668) vs 8.9% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
BMI SDS -0.254 vs -0.208 placebo score @ 26wk1.8 mg
absolute change · score
NCT01541215 · Phase 3
show 1 more result
-0.361 vs -0.166 placebo score @ 52wk1.8 mg
NCT01541215 · Phase 3
HbA1c Less Than 7 Without Hypoglycemia 52.5% (n=59) vs 36.2% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 31 Participants as posted
show 3 more results
39.3% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 22 Participants as posted
44.7% (n=76) vs 33% (n=88) Glargine @ 26wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
48.2% (n=83) vs 33% (n=94) Glargine @ 12wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
HbA1c Less Than 7 5 72.9% (n=59) vs 50% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 43 Participants as posted
show 1 more result
64.3% (n=56) vs 44.2% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 36 Participants as posted
HbA1c 7.13% (n=136) vs 7.68% (n=137) Glargine @ 26wk
absolute value · percentage points
HbA1C at 6 months post-intervention
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Weight Gain 33% (n=996) vs 23.5% (n=995) Oral Antidiabetic Drug @ 104wk1.8 mg
event count · % of participants
NCT02730377 · Phase 4 · registry result, not featured evidence · converted to % from 329 Participants as posted
show 8 more results
41% (n=78) vs 23.3% (n=90) Glargine @ 26wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
40.7% (n=361) vs 19% (n=179) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 147 Participants as posted
41.1% (n=180) vs 19% (n=179) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 74 Participants as posted
32.5% (n=302) vs 4.6% (n=151) Insulin Degludec @ 26wk*
Yes
NCT03175120 · Phase 3 · registry result, not featured evidence · converted to % from 98 Participants as posted
16% (n=275) vs 8.1% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 44 Participants as posted
52% (n=273) vs 8.1% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 142 Participants as posted
47.6% (n=105) vs 8.6% (n=105) Insulin Degludec @ 26wk*
Yes
NCT02911948 · Phase 3 · registry result, not featured evidence · converted to % from 50 Participants as posted
43.3% (n=210) vs 18.1% (n=210) IGlar @ 26wk*
Yes
NCT02773368 · Phase 3 · registry result, not featured evidence · converted to % from 91 Participants as posted
Weight -4.77 vs 0.6 Glargine Kgs @ 26wk
absolute change · Kgs
Weight change from baseline (discharge) to 6 months after discharge
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
BMI 32.7 vs 33.3 Glargine kg @ 26wk
absolute value · kg
BMI at 26 weeks follow up
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
Total Daily Insulin Dose 0 vs 20.9 Glargine per day @ 26wk
absolute value · per day
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
Heart Rate Bpm 83 vs 79 Glargine minutes @ 26wk
absolute value · minutes
Heart rate at 6 months post-discharge
NCT01919489 · Phase 4 · registry result, not featured evidence · combination

+ 101 further endpoints in the CSV export.

Semaglutide (Ozempic)

HbA1c 6.5 or Less 47% (n=404) vs 22% (n=405) Exenatide ER @ 56wk1.0 mg
event count · % of participants
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 190 Participants as posted
Chronic Dialysis 4.9% (n=1767) vs 5.7% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 87 Participants as posted
Renal Death 0.3% (n=1767) vs 0.3% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 5 Participants as posted
UACR 0.6 vs 0.89 placebo ratio @ 104wk
ratio to baseline · ratio
NCT03819153 · Phase 3
Non-fatal MI 2.9% (n=1767) vs 3.6% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 52 Participants as posted
MALE 0.9% (n=1767) vs 1.6% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
Acute Limb Ischemia 0.1% (n=1767) vs 0.2% (n=1766) placebo @ 234wk
event rate · % of participants
Acute limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 1 Participants as posted
Chronic Limb Ischemia Hospitalization 0.9% (n=1767) vs 1.4% (n=1766) placebo @ 234wk
event count · % of participants
Chronic limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
SBP -5.61 vs -2.29 Sitagliptin mmHg @ 56wk1.0 mg weekly
absolute change · mmHg
Systolic blood pressure
NCT01930188 · Phase 3 · combination
show 1 more result
-5.07 vs -2.29 Sitagliptin mmHg @ 56wk0.5 mg weekly
Systolic blood pressure
NCT01930188 · Phase 3 · combination
DTSQs 5.91 vs 4.45 Sitagliptin score @ 56wk1.0 mg weekly
absolute change · score
NCT01930188 · Phase 3 · combination
show 4 more results
5.37 vs 3.99 Insulin Glargine score @ 30wk1.0 mg/week
NCT02128932 · Phase 3
5.28 vs 4.45 Sitagliptin score @ 56wk0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.86 vs 3.99 Insulin Glargine score @ 30wk0.5 mg/week
NCT02128932 · Phase 3
4.56 vs 2.17 Insuline Glargine U100 (Titrated) score @ 40wk
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
SF-36 Bodily Pain 1.76 vs 0.9 Insulin Glargine score @ 30wk1.0 mg/week
absolute change · score
Bodily pain
NCT02128932 · Phase 3
show 4 more results
2.2 vs 1.5 Liraglutide score @ 30wk1.0 mg
Bodily pain
NCT03191396 · Phase 3 · registry result, not featured evidence
1.54 vs 1.69 Dulaglutide score @ 40wk1.0 mg
Bodily pain
NCT02648204 · Phase 3 · registry result, not featured evidence
0.95 vs 0.9 Insulin Glargine score @ 30wk0.5 mg/week
Bodily pain
NCT02128932 · Phase 3
0.96 vs 1.69 Dulaglutide score @ 40wk0.5 mg
Bodily pain
NCT02648204 · Phase 3 · registry result, not featured evidence
SF-36 General Health 2.78 vs 1.63 Insulin Glargine score @ 30wk1.0 mg/week
absolute change · score
General Health
NCT02128932 · Phase 3
show 4 more results
2.7 vs 1.6 Liraglutide score @ 30wk1.0 mg
General health
NCT03191396 · Phase 3 · registry result, not featured evidence
2.52 vs 1.86 Dulaglutide score @ 40wk1.0 mg
General health
NCT02648204 · Phase 3 · registry result, not featured evidence
1.95 vs 1.63 Insulin Glargine score @ 30wk0.5 mg/week
General Health
NCT02128932 · Phase 3
2.65 vs 1.86 Dulaglutide score @ 40wk0.5 mg
General health
NCT02648204 · Phase 3 · registry result, not featured evidence

+ 91 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

Liraglutide (Victoza)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: July 2028 · NCT07073053 (registry estimate)

Reported efficacy

Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)

Result source: NCT04560998

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLiraglutide (Victoza)Semaglutide (Ozempic)
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048—Not reported

LDL-C, % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Ozempic)
—Not reported

Non-HDL-C, % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Ozempic)
—Not reported

ApoB, % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Ozempic)
—Not reported

Lp(a), % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Ozempic)
—Not reported

3-point MACE (% with event)

Liraglutide (Victoza)
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048
Semaglutide (Ozempic)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Liraglutide (Victoza): 4 of 5 rows · Semaglutide (Ozempic): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Victoza)Semaglutide (Ozempic)
HbA1c
absolute change · percentage points
6.7% (n=27) vs 6.8% (n=28) placebo @ 26wka,b,c,d
NCT04881110 · Phase 4 · registry result, not featured evidence
-0.8% (n=304) vs 0.2% (n=311) placebo @ 52wka,b,c,d
NCT04560998 · Phase 3
Dropout rate
3%e
NCT01179048 · Phase 3
show 3 more results
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
10%
NCT04881110 · Phase 4 · registry result, not featured evidence
0%
NCT03010683 · Phase na · registry result, not featured evidence
7.6%e
NCT04560998 · Phase 3
Discontinued due to AEs
—e
NCT01179048 · Phase 3
show 3 more results
—
NCT03260881 · Phase 4 · registry result, not featured evidence
—
NCT04881110 · Phase 4 · registry result, not featured evidence
—
NCT03010683 · Phase na · registry result, not featured evidence
—e
NCT04560998 · Phase 3
Serious AEs
49.7%e
NCT01179048 · Phase 3
show 3 more results
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
0%
NCT04881110 · Phase 4 · registry result, not featured evidence
0%
NCT03010683 · Phase na · registry result, not featured evidence
18.7%e
NCT04560998 · Phase 3
Most frequent reported AEs
e
nausea 11.1% (placebo 2.8%)
diarrhoea 5.7% (placebo 2.2%)
NCT01179048 · Phase 3
show 1 more result
abdominal distention 31.6%
nausea 31.6%
NCT03260881 · Phase 4 · registry result, not featured evidence
e
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 26 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Victoza)

MACE 3-point Composite 13% (n=4668) vs 14.9% (n=4672) placebo @ 260wk
event count · % of participants
NCT01179048 · Phase 3
MACE Broad 20.3% (n=4668) vs 22.7% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
All-cause Mortality 8.2% (n=4668) vs 9.6% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Microvascular Composite 7.6% (n=4668) vs 8.9% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Tcpo2 54.2 vs 43.4 placebo mmHg @ 26wk
absolute change · mmHg
NCT04881110 · Phase 4 · registry result, not featured evidence
Fasting Glucose Change mg/dL 6.58 vs 6.49 placebo mmol/L @ 26wk
absolute change · mmol/L
NCT04881110 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 118.5 mg/dL as posted
BMI 28.7 vs 27.7 placebo kg @ 26wk
absolute change · kg
NCT04881110 · Phase 4 · registry result, not featured evidence
Waist Circumference Change 108.9 vs 104.1 placebo cm @ 26wk
absolute change · cm
NCT04881110 · Phase 4 · registry result, not featured evidence
CRP Change mg/dL 0.5 vs 0.8 placebo mg/dL @ 26wk
absolute change · mg/dL
NCT04881110 · Phase 4 · registry result, not featured evidence
Serum Creatinine Change mg/dL 1 vs 0.8 placebo mg/dL @ 26wk
absolute change · mg/dL
NCT04881110 · Phase 4 · registry result, not featured evidence
ABI 0.9 vs 1 placebo ratio @ 26wk
ratio to baseline · ratio
NCT04881110 · Phase 4 · registry result, not featured evidence
6MWD - Change 364 vs 340 placebo m @ 26wk
absolute change · m
NCT04881110 · Phase 4 · registry result, not featured evidence

Semaglutide (Ozempic)

Max Walking Distance 1.21 vs 1.08 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.16 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
VascuQoL-6 2 vs 1 placebo score @ 52wk
absolute change · score
NCT04560998 · Phase 3
Pain-free Walking Distance 1.21 vs 1.1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.18 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
Weight -5.2 vs -1.2 placebo kg @ 52wk
absolute change · kg
NCT04560998 · Phase 3
SBP -4 vs -1 placebo mmHg @ 52wk
absolute change · mmHg
NCT04560998 · Phase 3
Total Cholesterol 0.96 vs 1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
LDL Cholesterol 0.99 vs 1.03 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
HDL Cholesterol 1.04 vs 0.99 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
Triglyceride 0.8 vs 0.95 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
ABI 1.06 vs 1.02 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3
TBI 1.07 vs 1.04 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3
WIQ Global 9.48% (n=312) vs 6.51% (n=321) placebo @ 52wk
absolute change · percentage points
NCT04560998 · Phase 3

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Victoza)'s landscape · Semaglutide (Ozempic)'s landscape